SciClone Pharmaceuticals (Holdings) Limited

SZSC:6600 Stock Report

Market Cap: HK$11.4b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Hong Zhao

Chief executive officer

CN¥17.0m

Total compensation

CEO salary percentage45.0%
CEO tenure4yrs
CEO ownership0.2%
Management average tenure2yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hong Zhao's remuneration changed compared to SciClone Pharmaceuticals (Holdings)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥953m

Mar 31 2023n/an/a

CN¥904m

Dec 31 2022CN¥17mCN¥8m

CN¥855m

Sep 30 2022n/an/a

CN¥844m

Jun 30 2022n/an/a

CN¥833m

Mar 31 2022n/an/a

CN¥878m

Dec 31 2021CN¥26mCN¥7m

CN¥923m

Sep 30 2021n/an/a

CN¥837m

Jun 30 2021n/an/a

CN¥779m

Mar 31 2021n/an/a

CN¥766m

Dec 31 2020CN¥29mCN¥7m

CN¥754m

Sep 30 2020n/an/a

CN¥817m

Dec 31 2019CN¥15mCN¥6m

CN¥615m

Compensation vs Market: Hong's total compensation ($USD2.35M) is above average for companies of similar size in the Hong Kong market ($USD480.51K).

Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.

CEO

Hong Zhao (61 yo)

4yrs

Tenure

CN¥17,030,000

Compensation

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Leadership Team

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director4yrsCN¥17.03m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretaryless than a yearno data0.026%
HK$ 3.0m
Chihwen Shao
VP & Head of Technical Operations and Pharmacovigilance2.4yrsno datano data
Min Jia
VP & Head of Immunization Business Unitno datano datano data
Mingxiang Wu
VP and Head of Market Access & Commercial Operation (MACO) Departmentno datano datano data
Lianzong Wu
VP and Head of Registration & Pharmaceutical Affairs Departmentno datano datano data
Li Mao
VP, GM of Research and Development & Chief Medical Officer2yrsno datano data
Min Wu
VP & Chief Business Development Officerless than a yearno datano data

2.0yrs

Average Tenure

55yo

Average Age

Experienced Management: 6600's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director4yrsCN¥17.03m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretary1.1yrsno data0.026%
HK$ 3.0m
Daniel Vasella
Non-Executive Director3.8yrsCN¥658.00kno data
Guoen Liu
Independent Non-Executive Director3.3yrsCN¥658.00kno data
Zhenfu Li
Non-Executive Chairman4yrsno datano data
Wendy Hayes
Independent Non-Executive Director3.3yrsCN¥658.00kno data
Haixia Wang
Non-Executive Director3yrsno datano data
Yi-Hsien Lin
Non-Executive Director3.3yrsno datano data
Ping Chen
Independent Non-Executive Director3.3yrsCN¥658.00kno data
Yushao Gu
Independent Non-Executive Director3.3yrsCN¥658.00kno data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: 6600's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/22 18:37
End of Day Share Price 2024/06/21 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SciClone Pharmaceuticals (Holdings) Limited is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullB. Riley Wealth
Hamed KhorsandBWS Financial Inc.
Hangci ZhengChina International Capital Corporation Limited